Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 | P54289 | 4/20 | 0.45 |
| ▸ | CACNA1B | Q00975 | 4/20 | 0.45 |
| ▸ | CACNB1 | Q02641 | 4/20 | 0.45 |
| ▸ | CACNA1C | Q13936 | 3/20 | 0.45 |
| ▸ | PDE4A | P27815 | 4/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.45 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.45 |
| ▸ | FKBP1A | P62942 | 5/20 | 0.42 |
| ▸ | PTAFR | P25105 | 1/20 | 0.41 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.40 |
| ▸ | FKBP4 | Q02790 | 1/20 | 0.40 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7594736 | 0.73 | FNTA (0.47) | CACNA1G | |
| SCHEMBL7595694 | 0.73 | AVPR1B (0.48) | PDE4APDE4BPDE4CPDE4DPOLB | |
| SCHEMBL7597214 | 0.70 | FNTA (0.42) | CACNA2D1CACNA1BCACNB1 | |
| SCHEMBL31350736 | 0.67 | FNTA (0.76) | CACNA2D1CACNA1BCACNB1CACNA1CKMT2A | |
| SCHEMBL6423229 | 0.66 | PDE4A (0.76) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6823690 | 0.65 | PDE4A (0.68) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6822891 | 0.65 | PDE4A (0.67) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL5265376 | 0.64 | CACNA2D1 (0.83) | CACNA2D1CACNA1BCACNB1CACNA1CCACNA1G | |
| SCHEMBL5267851 | 0.64 | CACNA2D1 (1.00) | CACNA2D1CACNA1BCACNB1CACNA1CCACNA1G | |
| SCHEMBL4753324 | 0.63 | MAOB (0.64) | CACNA2D1CACNA1BCACNB1CACNA1CPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020119979-A1 | Acyclic compounds and methods for treating multidrug resistance | PROCTER & GAMBLE COMPANY, THE | 2002-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119979-A1 | Acyclic compounds and methods for treating multidrug resistance | ABCC1, ABCB1, ABCB11 | CACNA2D1 3551/4885CACNA1B 3158/4885CACNB1 3009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.